A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis: comment on the article by Maksymowych et al.
Singh
Ranju
R
Menon
Yamini
Y
Cuchacovich
Raquel
R
Espinoza
Luis R
LR
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D004311:Double-Blind Method; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced*; D008297:Male; D000077268:Pamidronate; D016032:Randomized Controlled Trials as Topic; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004164:Diphosphonates; D000077268:Pamidronate